Taysha Gene Therapies, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Laura Sepp-Lorenzino, Ph.D.

Taysha Gene Therapies, Inc.’s own tally for this item (“Elect Director: Laura Sepp-Lorenzino, Ph.D.”): 150,094,517 for, 54,790,109 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The votes were cast as follows: Broker Non-Votes: 38,973,186 Both nominees were elected.”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 27,854,046 for, 4,676,230 withheld, 4,631,272 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Sean P. Nolan

Taysha Gene Therapies, Inc.’s own tally for this item (“Elect Director: Sean P. Nolan”): 169,142,295 for, 35,742,331 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The votes were cast as follows: Broker Non-Votes: 38,973,186 Both nominees were elected.”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 35,557,327 for, 1,542,949 withheld, 61,272 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Taysha Gene Therapies, Inc.’s own tally for this item (“3. Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement”): 168,142,551 for, 36,396,784 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 35,345,125 for, 1,816,423 against, 41,800 withheld, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 151 managers: 120,729,300 for, 36,489,292 against, 105 abstained, 36,482 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO INDICATE, ON A NON-BINDING ADVISORY BASIS, THE PREFERRED FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 47 managers: 181,920 for, 36,979,192 1 year, 422 unknown, 12 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 144 managers: 1,779,812 for, 36,482 against, 145,261,212 1 year, 390,590 3 year, 4,160 2 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026.

Taysha Gene Therapies, Inc.’s own tally for this item (“2. Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026”): 243,814,085 for, 25,551 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 37,161,548 for.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.